<DOC>
	<DOCNO>NCT01800682</DOCNO>
	<brief_summary>The purpose study evaluate dose proportionality pharmacokinetics ( explores body drug ) tramadol healthy adult participant .</brief_summary>
	<brief_title>A Pharmacokinetic Study Evaluate Dose-Proportionality Tramadol ( ULTRAM ) Extended-Release ( ER ) Healthy Participants</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , single-center , randomize ( study drug assign chance ) , 3-way crossover ( method use switch participant one study group another clinical trial ) study tramadol extended-release ( ER ) . All participant randomly assign 1 6 possible treatment sequence tramadol . The study consist 3 part : Screening ( within 20 day study commences Day -1 ) ; Open-label treatment ( consist 3 single-dose treatment period separate washout period 4-14 day , dose fasting condition Day 1 treatment period ) ; Follow-up ( 48-hour blood sample collection Day 3 Period 3 ) . The duration study anticipate 6-8 week per participant . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Tramadol</mesh_term>
	<criteria>Females negative pregnancy test Screening Day 1 treatment period Postmenopausal Females ( spontaneous menses least 2 year ) , surgically sterile , abstinent , , sexually active , practice effective method birth control Body mass index ( BMI ; weight kilogram [ kg ] divide height square meter [ m^2 ] ) 18 30 kilogram per square meter ( kg/m^2 ) , body weight less 50 kg Blood pressure ( participant supine 5 minute average minimum 2 reading take interval least 1 minute ) 90 140 millimeter mercury ( mmHg ) systolic ( top number blood pressure , pressure active contraction heart ) , high 90 mmHg diastolic ( low number blood pressure read pertain rest relaxation phase heart beat ) NonSmoker History current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia ) , lipid abnormality , significant pulmonary disease , include bronchospasmic respiratory disease , diabetes mellitus , renal hepatic insufficiency , thyroid disease , neurologic psychiatric disease , infection , illness investigator considers exclude participant could interfere interpretation study result Clinically significant abnormal value laboratory test Screening Clinically significant abnormal physical examination , vital sign electrocardiogram Screening Use prescription nonprescription medication ( include monoamine oxidase inhibitor , laxative , vitamin , herbal supplement ) , except acetaminophen , oral contraceptive hormonal replacement therapy within 30 day first dose study drug schedule History drug alcohol abuse within past 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Tramodol</keyword>
	<keyword>Ultram</keyword>
</DOC>